Health researchers in Africa are joining forces with experts at The University of Queensland in the quest for a new global drug development.
The University of Queensland (UQ) and African Network for Drugs and Diagnostics Innovation (ANDI) signed a Memorandum of Understanding (MoU) to facilitate Drug Discovery in Africa.
UQ’s Community for Open Antimicrobial Drug Discovery (CO-ADD) based at the Institute for Molecular Bioscience (IMB) has signed a Memorandum of Understanding (MOU) with the African Network for Drugs and Diagnostics Innovation (ANDI) which is hosted by the United Nations Office for Project Services (UNOPS).
The MoU commits the two institutions to partner in collaborative scientific capacity building, cross-promotion of research programs, experience sharing, learning and capacity building, joint development of funding applications, joint organization of trainings, conferences, seminars, and other academic meetings, as well as specific scientific, technical or administrative programs.
CO-ADD Director Professor Matthew Cooper said the partnership will create an opportunity for CO-ADD to enhance collaborations in health R&D and innovation in Africa.
“We are challenging current paradigms and the challenges of the pharmaceutical industry to discover new antibiotics, and partners such as the Pan-African Network for Drugs and Diagnostics Innovation help CO-ADD realise our vision of developing new treatments,” he said.
“This collaboration has a potential for selected African research institutions including ANDI’s Centres of Excellence to have free access to UQ’s antimicrobial screening program, and help generate scientific publication and intellectual property to support new drug discovery in the African continent,” he said.
ANDI Executive Director Dr Solomon Nwaka said the MoU was a positive step in the right direction.
“The partnership with UQ is an exciting technology transfer between the Northern and Southern hemispheres to advance the discovery of new chemical entities with potential to contribute to the fight against antimicrobial resistance,” he said.
Original press release: http://www.co-add.org/blog/205